Price Chart

Profile

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
URL https://www.sanofi.com
Investor Relations URL https://www.sanofi.com/en/investors
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Apr. 26, 2024 (est.)
Last Earnings Release Feb. 01, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 30, 2023

Profile

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
URL https://www.sanofi.com
Investor Relations URL https://www.sanofi.com/en/investors
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Apr. 26, 2024 (est.)
Last Earnings Release Feb. 01, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date May. 30, 2023